AlphaGrep UK
CORT icon

AlphaGrep UK’s Corcept Therapeutics CORT Stock Holding History

AlphaGrep UK’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$292K Buy
+2,531
New +$272K 0.09% 500

Other funds holding CORT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Ingalls & Snyder LLC
Ingalls & Snyder LLC New York $3.91B AUM 60.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

AlphaGrep UK's CORT Position: Q3 2026 in Review

AlphaGrep UK opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 2,531 shares worth $292K. The stake represents 0.09% of the portfolio and ranks #500 among its holdings.

403 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • AlphaGrep UK held 2,531 shares of Corcept Therapeutics worth $292K as of Q3 2026.
  • Corcept Therapeutics was a new AlphaGrep UK position in Q3 2026.
  • Corcept Therapeutics made up 0.09% of AlphaGrep UK's portfolio in Q3 2026, its #500 holding.
  • 403 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.